At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed initially unresectable MSS/pMMR RAS-mutant metastatic colorectal adenocarcinoma
- ✓No anti-tumor treatment after recurrence and metastasis (first-line)
- ✓At least one measurable lesion per RECIST v1.1
- ✓Ability to swallow oral medications
- ✕Prior bevacizumab or anti-CTLA4, anti-PD-1/PD-L1 immunotherapy
- ✕Symptomatic peripheral neuropathy >grade 2
- ✕Uncontrolled CNS metastasis or other CNS diseases
- ✕Active hepatitis B or C (except cured/negative cases)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05970302Phase 2RecruitingUpdate OverdueUpdated 35mo ago · Completion was 12mo agoXELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.
In Brief
A Phase 2 clinical trial evaluating Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine for Tislelizumab and 7 related conditions. Currently recruiting, targeting 52 participants across 1 site.
Signals
Detailed Summary
The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.
Study Details
Timeline
Interventions
Use the above medications on a regular basis.